|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients undergoing p-PCI for STEMI, MEA platelet function observed in coronary arteries was consistent with peripheral artery blood's independently of the antiplatelet drug used.
|
29575927 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
US respondents used TRA less commonly for primary PCI for STEMI than their global counterparts.
|
30456913 |
2019 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Use of the CADILLIAC Risk Score can accurately identify patients for safe early discharge after PCI for STEMI.
|
28612413 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients in group 1 underwent elective angioplasty and stenting, whereas all patients included in groups 2 and 3 suffered from acute coronary syndromes (STEMI or NSTEMI) and underwent urgent PCI.
|
28425039 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
We pooled patients with STEMI discharged on prasugrel in 2 prospective registries (Bern PCI Registry [NCT02241291] and SPUM-ACS (Inflammation and Acute Coronary Syndromes) [NCT01000701]) and 1 STEMI trial (COMFORTABLE-AMI (Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction) [NCT00962416]).
|
29654204 |
2018 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Door-to-balloon (DTB) time ≤90 min is an important quality indicator in the management of ST-elevation myocardial infarction (STEMI), but a considerable number of patients still do not meet this goal, particularly in countries outside the USA and Europe.Methods and Results:We analyzed 2,428 STEMI patients who underwent primary PCI ≤12 h of symptom onset who were registered in an ongoing prospective multicenter database (JCD-KiCS registry), between 2008 and 2013.
|
28228609 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
This highlights the persistently dramatic impact of SCA on STEMI and the major importance of PCI in this setting.
|
30608874 |
2019 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The indication for PCI was chronic stable angina in 46.1% (n=26), non-ST elevation acute coronary syndrome (NSTEACS) in 33.3% (n=18) and ST-elevation myocardial infarction (STEMI) in 18.5% (n=10) of patients.
|
31130523 |
2020 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite primary PCI being the well-established therapy, there are rooms for further research to optimize STEMI outcomes.
|
27846459 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
From 2007 to 2014, 1,525 consecutive patients (79% men, mean age 61 years) who underwent primary percutaneous coronary intervention for STEMI in the INTERSTELLAR (Incheon-Bucheon Cohort of Patients Undergoing Primary PCI for Acute ST-Elevation Myocardial Infarction) cohort were analyzed retrospectively.
|
28214004 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antithrombotic therapy for patients with STEMI undergoing primary PCI.
|
28230176 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, STEMI (OR 1.61; CI 1.52-1.71), performed PCI (OR 2.65; CI 2.42-2.90) and Killip class >2 (OR 1.58; CI 1.36-1.84) favoured referral for CR, while age > 65 years, previous myocardial infarction, cerebrovascular disease or peripheral artery disease had a negative impact on referral for CR.
|
29657032 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aims to discuss the efficacy and safety of the application of thrombus aspiration catheters during emergency PCI operations for acute ST-elevation myocardial infarction (STEMI) patients with high thrombus load.
|
31547844 |
2019 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Changes in heme-metabolism were characterized in a second STEMI-group by a dual proteomic approach analyzing in-vivo aspirated coronary thrombi at PCI (N=24) and the associated peripheral-blood changes (N=10).
|
28837209 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
During hospitalization, Patients in prior BBs group were more likely to develop decompensated heart failure (9.9% vs. 3.6%, P<0.001), less likely to have STEMI (33.9% vs. 54.4%, P<0.001), and subsequently less PCI (73.2% vs. 81.3%, P=0.002), but higher inpatient mortality (8.8% vs. 4.8%, P=0.009).
|
28747039 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results support the use of DES during primary PCI for STEMI.
|
28865897 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients with STEMI and LV dysfunction doxycycline can favorably modulate the LV filling pattern early after primary PCI.
|
28433557 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognosis and first diagnostic ECG in STEMI patients referred to the emergency medical system for primary PCI.
|
30497744 |
2019 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined LVEDP/LVEF assessment was useful in predicting MACE after successful PCI for STEMI patients and could facilitate risk stratification, as it predicts LV remodeling.
|
29143103 |
2018 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this single-center prospective randomized study, patients with subacute STEMI presenting ≥12 and ≤48 h after symptom onset were randomized to primary PCI with or without manual TA in a 1:1 ratio.
|
29869443 |
2018 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Low risk patients identified using CADILLAC risk score with STEMI treated successfully with primary PCI have a low adverse event rate on the third day or later of hospitalization suggesting that an earlier discharge is safe in properly selected patients.
|
27896906 |
2017 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
|
24952855 |
2014 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The records were reviewed for patients admitted to the large comprehensive university hospital for PCI due to STEMI from January 1, 2002 to January 1, 2017.
|
28511806 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of the current study was to assess the prognostic value of ACEF scores in acute ST-segment elevation myocardial infarction (STEMI) patients with non-IRA CTO after successful primary PCI.
|
28940388 |
2018 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We chose the acute ST-elevation myocardial infarction (ASTEMI) patients treated with direct PCI to compare different administration routes of diltiazem.
|
30223281 |
2018 |